A Trial of LY3056480 in Patients With SNLH

Summary

A phase 2 trial with LY3056480 in patients with stable SNHL

Timeline

Start

2022-09

Primary completion

2024-09

Completion

2025-03

Outcome

Missed primary endpoint

Stopped: “Study put on hold”

release “Pre-defined Primary Endpoints in the Phase IIa part were not met.” audiontherapeutics.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3056480	Unknown	250 ug	Other

Indications